# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Wells Fargo analyst Mohit Bansal maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price targ...
New Investigator-Led Study Shows VOXZOGO Significantly Increased Bone Length While Maintaining Bone Strength Through 5 Years of...
Data from Longest and Largest Hemophilia Gene Therapy Study Show Durable and Sustained Bleed Control and Factor VIII Expression...
Last week, these 10 large-cap stocks had the worst performance. NICE, PBR, FIX, LI, MLM, VMC, BMRN, EDU, GFI, MUFG all saw sign...
Baird analyst Joel Beatty downgrades Biomarin Pharmaceutical (NASDAQ:BMRN) from Outperform to Neutral and lowers the price t...